Literature DB >> 17209060

A sequence variation scan of the coagulation factor VIII (FVIII) structural gene and associations with plasma FVIII activity levels.

Kevin R Viel1, Deepa K Machiah, Diane M Warren, Manana Khachidze, Alfonso Buil, Karl Fernstrom, Juan C Souto, Juan M Peralta, Todd Smith, John Blangero, Sandra Porter, Stephen T Warren, Jordi Fontcuberta, Jose M Soria, W Dana Flanders, Laura Almasy, Tom E Howard.   

Abstract

Plasma factor VIII coagulant activity (FVIII:C) level is a highly heritable quantitative trait that is strongly correlated with thrombosis risk. Polymorphisms within only 1 gene, the ABO blood-group locus, have been unequivocally demonstrated to contribute to the broad population variability observed for this trait. Because less than 2.5% of the structural FVIII gene (F8) has been examined previously, we resequenced all known functional regions in 222 potentially distinct alleles from 137 unrelated nonhemophilic individuals representing 7 racial groups. Eighteen of the 47 variants identified, including 17 single-nucleotide polymorphisms (SNPs), were previously unknown. As the degree of linkage disequilibrium across F8 was weak overall, we used measured-genotype association analysis to evaluate the influence of each polymorphism on the FVIII:C levels in 398 subjects from 21 pedigrees known as the Genetic Analysis of Idiopathic Thrombophilia project (GAIT). Our results suggested that 92714C>G, a nonsynonymous SNP encoding the B-domain substitution D1241E, was significantly associated with FVIII:C level. After accounting for important covariates, including age and ABO genotype, the association persisted with each C-allele additively increasing the FVIII:C level by 14.3 IU dL(-1) (P = .016). Nevertheless, because the alleles of 56010G>A, a SNP within the 3' splice junction of intron 7, are strongly associated with 92714C>G in GAIT, additional studies are required to determine whether D1241E is itself a functional variant.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17209060      PMCID: PMC1874571          DOI: 10.1182/blood-2006-06-026104

Source DB:  PubMed          Journal:  Blood        ISSN: 0006-4971            Impact factor:   22.113


  79 in total

1.  Association of fibrinogen and coagulation factors VII and VIII with cardiovascular risk factors in the elderly: the Cardiovascular Health Study. Cardiovascular Health Study Investigators.

Authors:  M Cushman; D Yanez; B M Psaty; L P Fried; G Heiss; M Lee; J F Polak; P J Savage; R P Tracy
Journal:  Am J Epidemiol       Date:  1996-04-01       Impact factor: 4.897

2.  Dose-response and trend analysis in epidemiology: alternatives to categorical analysis.

Authors:  S Greenland
Journal:  Epidemiology       Date:  1995-07       Impact factor: 4.822

3.  cis-acting elements and transcription factors involved in the promoter activity of the human factor VIII gene.

Authors:  M S Figueiredo; G G Brownlee
Journal:  J Biol Chem       Date:  1995-05-19       Impact factor: 5.157

4.  Role of the liver-enriched transcription factor hepatocyte nuclear factor 1 in transcriptional regulation of the factor V111 gene.

Authors:  L K McGlynn; C R Mueller; M Begbie; C R Notley; D Lillicrap
Journal:  Mol Cell Biol       Date:  1996-05       Impact factor: 4.272

5.  Large increase in plasmatic 11-dehydro-TxB2 levels due to oral contraceptives.

Authors:  A F Schlit; P Grandjean; J Donnez; E Lavenne
Journal:  Contraception       Date:  1995-01       Impact factor: 3.375

6.  Hemostatic factors in the Coronary Artery Risk Development in Young Adults (CARDIA) Study.

Authors:  D Green; K J Ruth; A R Folsom; K Liu
Journal:  Arterioscler Thromb       Date:  1994-05

7.  Normal variation at the myotonic dystrophy locus in global human populations.

Authors:  C Zerylnick; A Torroni; S L Sherman; S T Warren
Journal:  Am J Hum Genet       Date:  1995-01       Impact factor: 11.025

8.  Role of clotting factor VIII in effect of von Willebrand factor on occurrence of deep-vein thrombosis.

Authors:  T Koster; A D Blann; E Briët; J P Vandenbroucke; F R Rosendaal
Journal:  Lancet       Date:  1995-01-21       Impact factor: 79.321

9.  Post-translational requirements for functional factor V and factor VIII secretion in mammalian cells.

Authors:  D D Pittman; K N Tomkinson; R J Kaufman
Journal:  J Biol Chem       Date:  1994-06-24       Impact factor: 5.157

10.  Absence of mutations at the activated protein C cleavage sites of factor VIII in 125 patients with venous thrombosis.

Authors:  J C Roelse; M M Koopman; H R Büller; J W ten Cate; B Montaruli; J A van Mourik; J Voorbert
Journal:  Br J Haematol       Date:  1996-03       Impact factor: 6.998

View more
  28 in total

1.  Pharmacogenetics and the immunogenicity of protein therapeutics.

Authors:  Chen Yanover; Nisha Jain; Glenn Pierce; Tom E Howard; Zuben E Sauna
Journal:  Nat Biotechnol       Date:  2011-10-13       Impact factor: 54.908

Review 2.  Key issues in inhibitor management in patients with haemophilia.

Authors:  Keith Gomez; Robert Klamroth; Johnny Mahlangu; Maria E Mancuso; María E Mingot; Margareth Castro Ozelo
Journal:  Blood Transfus       Date:  2013-12-03       Impact factor: 3.443

3.  Factor VIII gene variants and inhibitor risk in African American hemophilia A patients.

Authors:  Devi Gunasekera; Ruth A Ettinger; Shelley Nakaya Fletcher; Eddie A James; Maochang Liu; John C Barrett; Janice Withycombe; Dana C Matthews; Melinda S Epstein; Richard J Hughes; Kathleen P Pratt
Journal:  Blood       Date:  2015-01-23       Impact factor: 22.113

Review 4.  Inherited risk factors for venous thromboembolism.

Authors:  Ida Martinelli; Valerio De Stefano; Pier M Mannucci
Journal:  Nat Rev Cardiol       Date:  2014-01-14       Impact factor: 32.419

Review 5.  The intron-22-inverted F8 locus permits factor VIII synthesis: explanation for low inhibitor risk and a role for pharmacogenomics.

Authors:  Zuben E Sauna; Jay N Lozier; Carol K Kasper; Chen Yanover; Timothy Nichols; Tom E Howard
Journal:  Blood       Date:  2014-11-18       Impact factor: 22.113

6.  Novel approach to genetic analysis and results in 3000 hemophilia patients enrolled in the My Life, Our Future initiative.

Authors:  Jill M Johnsen; Shelley N Fletcher; Haley Huston; Sarah Roberge; Beth K Martin; Martin Kircher; Neil C Josephson; Jay Shendure; Sarah Ruuska; Marion A Koerper; Jaime Morales; Glenn F Pierce; Diane J Aschman; Barbara A Konkle
Journal:  Blood Adv       Date:  2017-05-18

Review 7.  Haemophilia management: time to get personal?

Authors:  T E Howard; C Yanover; J Mahlangu; A Krause; K R Viel; C K Kasper; K P Pratt
Journal:  Haemophilia       Date:  2011-06-08       Impact factor: 4.287

8.  Most factor VIII B domain missense mutations are unlikely to be causative mutations for severe hemophilia A: implications for genotyping.

Authors:  K Ogata; S R Selvaraj; H Z Miao; S W Pipe
Journal:  J Thromb Haemost       Date:  2011-06       Impact factor: 5.824

9.  Complexity and diversity of F8 genetic variations in the 1000 genomes.

Authors:  J N Li; I G Carrero; J F Dong; F L Yu
Journal:  J Thromb Haemost       Date:  2015-10-20       Impact factor: 5.824

Review 10.  Immune response to FVIII in hemophilia A: an overview of risk factors.

Authors:  Kanjaksha Ghosh; Shrimati Shetty
Journal:  Clin Rev Allergy Immunol       Date:  2009-10       Impact factor: 8.667

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.